TY - JOUR
AU - Finlayson, Donald
AB - This retrospective chart review of 155 patients having coronary artery bypass graft surgery (CABG) over a two-month period determined whether the use of a cell saver apparatus (CSA) (1) reduced or increased the requirements for homologous blood; (2) increased the incidence of postsurgical bleeding; (3) was costeffective. Two groups of patients were identified. Group 1 (n = 99) received both CSA processed red blood cells and homologous blood components. Requirement for homologous blood products was reduced in the first 24 hr after surgery (0.5 ± 1.0 vs 1.3 ± 1.8 units; P < 0.05) when compared with Group 2 (n = 56) in whom only homologous blood products were utilized. More patients in Group 1 had no transfusion requirements (45 vs 8; P < 0.05) and there was no increased risk of major haemorrhage. When the capital costs are included, utilization of the CSA was not costeffective. We conclude that utilisation of a CSA was safe, with no increased risk of bleeding, reduced requirements for homologous blood transfusions, but added to the cost of the procedure.
TI - The benefit of the Hemonetics® cell saver apparatus during cardiac surgery
JO - Canadian Journal of Anesthesia/Journal canadien d'anesthésie
DO - 10.1007/BF03006478
DA - 2008-12-06
UR - https://www.deepdyve.com/lp/springer-journals/the-benefit-of-the-hemonetics-cell-saver-apparatus-during-cardiac-rXNtQ27jmh
SP - 618
EP - 623
VL - 37
IS - 6
DP - DeepDyve
ER -